SRRA News
Archived Headlines
- More capital for Canadian cancer cures: ProNAi Therapeutics increases proposed IPO deal size by 37% 07/15/15
- Week ahead: 8 IPOs planned for the week of July 13 07/13/15
- Canadian cancer biotech ProNAi Therapeutics sets terms for $101 million IPO 07/06/15
- Something good out of Canada: Cancer biotech ProNAi Therapeutics files for an $86 million IPO 06/12/15
Microcap biotech Benitec Biopharma revives US IPO with 61% lower deal size and warrants
Benitec Biopharma, which is developing a gene therapy platform based on DNA-directed RNA interference, reduced the number of ADSs it plans to offer, added warrants and replaced the lead underwriter ahead of its upcoming IPO on Monday. It had been scheduled to...read more
July IPO activity was below average; will August outperform expectations?
17 IPOs in July raised $2.8 billion in proceeds, falling far short of the 33 IPOs that raised $8.2 billion in July 2014. Year-to-date, 121 companies have gone public in 2015,...read more
US IPO Weekly Recap: IPO market back on track as tech and biotech deals fly up over 50%
The IPO market saw sevens this past week. Seven IPOs raised $700 million. Cybersecurity firm Rapid7 spiked 56% on its offering, while cancer biotech ProNAi Therapeutics (+76%) had the seventh-best debut of 2015 and home phone provider Ooma had the...read more
ProNAi Therapeutics prices IPO at $17
ProNAi Therapeutics, which is developing cancer therapies based on DNA interference, raised $138 million by offering 8.1 million shares at $17. ProNAi Therapeutics plans to list on the NASDAQ under the symbol DNAI. ProNAi Therapeutics initially filed...read more